Anti-tuberculosis combination regimen

This page covers all Anti-tuberculosis combination regimen drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Multiple: ATP synthase (bedaquiline), cell wall synthesis (pretomanid), ribosomal protein synthesis (linezolid), DNA gyrase (moxifloxacin).

Targets

Multiple: ATP synthase (bedaquiline), cell wall synthesis (pretomanid), ribosomal protein synthesis (linezolid), DNA gyrase (moxifloxacin)

Marketed (1)

• BPaL(M) regimen · Asan Medical Center · Infectious Disease
  BPaL(M) is a combination regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin that targets multiple pathways in Mycobacterium tuberculosis to overcome drug resistance.

Patent intelligence

• tuberculosis combination regimen patent landscape — aggregated cliff calendar, attackable patents, originator estates